Adults With HIV, Obesity Who Switch ART Regimens Do Not Have Clinically Meaningful Weight Loss, Trial Shows

MedPage Today (7/17, Haelle) reports, “Adults with HIV and obesity who switched from an antiretroviral therapy (ART) regimen with an integrase strand transfer inhibitor (INSTI) and tenofovir alafenamide to doravirine with or without tenofovir disoproxil fumarate did not have clinically meaningful weight loss, a randomized trial showed.” Researchers found that “at 48 weeks of follow-up, the median weight change was -0.47%...in those who switched to doravirine and tenofovir alafenamide/emtricitabine, -2.73%...in those who switched to doravirine and tenofovir disoproxil fumarate/emtricitabine, and -1.84%...in those who continued the INSTI and tenofovir alafenamide/emtricitabine.” The findings were presented at the International AIDS Society Conference on HIV Science.